Cetirizine

Lore & Background

Cetirizine was patented in 1983 by UCB and came into medical use in 1987. It is available as a generic medication and in 2023 was the 55th most commonly prescribed medication in the United States, with more than 11 million prescriptions. The drug is available over-the-counter in the US in 5 and 10 mg tablets, with a 20 mg strength available by prescription only, and as a 1 mg/mL syrup by prescription. In the UK, up to 30 tablets of 10 mg are on the general sales list and can be purchased without a prescription or pharmacist supervision.

Reader's Guide

Cetirizine is significant as a second-generation antihistamine that provides effective relief for allergic rhinitis, urticaria, and related conditions with less sedation than first-generation antihistamines like diphenhydramine. Its degree of benefit is similar to other antihistamines, but among second-generation drugs, cetirizine is more likely than fexofenadine and loratadine to cause drowsiness, while showing superior efficacy in the histamine-induced wheal and flare paradigm and tending to produce slightly greater clinical symptom relief than fexofenadine. The drug is listed on the World Health Organization's List of Essential Medicines as a therapeutic alternative. Common side effects include sleepiness, dry mouth, headache, and abdominal pain. A notable adverse effect is pruritus after discontinuation of prolonged use (typically beyond six months), which the FDA analyzed and supported as causally related. Cetirizine is not metabolized by the cytochrome P450 system, so it does not interact significantly with drugs that inhibit or induce those enzymes.

Therapeutic Reach and Clinical Standing

Cetirizine occupies a central place in modern allergy management. As a second-generation, peripherally selective antihistamine, it is indicated for allergic rhinitis, dermatitis, urticaria, and runny nose, with effects typically emerging within thirty minutes and persisting for roughly a full day. Its therapeutic benefit is broadly comparable to first-generation agents like diphenhydramine, yet it achieves this with a more favorable side-effect profile. Among its peers in the second-generation class, cetirizine stands out for superior efficacy in the histamine-induced wheal-and-flare paradigm and for producing slightly greater clinical symptom relief than fexofenadine, which itself edges out loratadine—a drug that failed to demonstrate significant superiority over placebo. It is particularly effective for both acute and, in select cases, chronic hives, outperforming other second-generation options in that setting. Recognized as a therapeutic alternative on the WHO List of Essential Medicines and available as a generic, cetirizine reached the 55th most prescribed medication in the United States in 2023, with over eleven million prescriptions dispensed.

Receptor Selectivity and the Sedation Question

At the molecular level, cetirizine is a highly selective antagonist of the histamine H1 receptor, with a Ki of approximately 6 nM. It demonstrates at least 600-fold selectivity over muscarinic, serotonergic, dopaminergic, and adrenergic sites, and more than 20,000-fold selectivity over the five muscarinic acetylcholine receptors, effectively eliminating anticholinergic side effects. Its negligible hERG channel inhibition and the absence of cardiotoxicity at doses up to 60 mg per day—six times the standard dose—further underscore its safety margin. The drug crosses the blood-brain barrier only minimally. PET imaging revealed that a 10 mg dose occupies just 12.6% of brain H1 receptors, well below the 50% threshold associated with significant somnolence and cognitive decline. By contrast, 30 mg of hydroxyzine achieves 67.6% occupancy. This explains why cetirizine at 5 to 10 mg is generally non-sedating or only mildly sedating, while the 20 mg dose can induce noticeable drowsiness. Among second-generation antihistamines, however, cetirizine remains more likely than fexofenadine or loratadine to cause drowsiness.

The Pruritus Rebound and Adverse-Effect Landscape

While cetirizine's common side effects—headache, dry mouth, drowsiness, fatigue, and abdominal pain—are generally mild, a rarer and more troubling phenomenon has drawn regulatory attention. Patients who discontinue the medication after prolonged daily use, typically beyond six months, may experience severe generalized itching, or pruritus, within days of stopping. The precise mechanism remains unknown, but the FDA's analysis of its Adverse Event Reporting System database and published literature through April 2017 supported a causal link. Some affected patients reported that the itching disrupted their ability to work, sleep, or carry out routine activities. On 16 May 2025, the FDA issued a Drug Safety Communication covering both cetirizine and levocetirizine. The agency noted that symptoms generally resolve upon restarting the medication and that, in some individuals, a gradual weaning approach mitigated the reaction, though no specific tapering schedule is provided in the drug's labeling. More serious but rare adverse effects include tachycardia and edema.

Access, Formulations, and Special Populations

Cetirizine was patented by UCB in 1983 and entered medical use in 1987. Today it is widely available as a generic in tablets, capsules, and oral syrup. In the United States, 5 mg and 10 mg tablets are sold over the counter, while a 20 mg strength and a 1 mg/mL syrup require a prescription. In the United Kingdom, up to thirty 10 mg tablets appear on the general sales list, allowing purchase without a prescription or pharmacist supervision. The medication is approved for paediatric patients, with somnolence being the primary side effect warranting caution in younger users. Regarding reproductive considerations, evidence suggests cetirizine appears safe during pregnancy, though use during breastfeeding is not recommended. Its peripherally selective mechanism—blocking H1 receptors predominantly outside the central nervous system—underpins its favorable tolerability profile across these diverse patient groups, making it a practical, accessible option for managing histamine-driven allergic conditions worldwide.

Gallery